Efficacy News and Research

RSS

Updates on development of Truvada and TMC278

Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).

21 Apr 2010

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.

21 Apr 2010

Liquidia Technologies adds PPD to Series C financing

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that it has added an additional investor, PPD, Inc., to its Series C financing. The final addition of PPD brings the total funding for this round to $25 million.

21 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

Endosense releases TactiCath force-sensing ablation catheter

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the commercial release of its next generation TactiCath force-sensing ablation catheter. Recently granted CE mark and unveiled this month at the DGK 2010 - German Cardiac Society meeting in Mannheim, Germany, the second generation product includes an elegantly enhanced catheter along with a feature-rich supporting system called the TactiSys™.

20 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

AngioDynamics commences treatment in NanoKnife IRE System pilot study for HCC

AngioDynamics today announced the first patient treatment and growing enrollment in a pilot study of the use of the Company's NanoKnife® Irreversible Electroporation (IRE) System in the treatment of early stage hepatocellular carcinoma (HCC), or primary liver cancer. This clinical trial is being conducted under the supervision of Professor Jordi Bruix of the Barcelona Clinic Liver Cancer Group of the University of Barcelona and Professor Riccardo Lencioni of the University of Pisa School of Medicine.

20 Apr 2010

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.

20 Apr 2010

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

Researchers have found that polytherapy with multiple anti-epileptic drugs did not result in greater adverse effects than monotherapy for patients with refractory epilepsy. This observational study also found AED load was not a factor in causing adverse effects, but suggests that individual susceptibility, type of AEDs used, and physicians' skills determine which patients suffer adverse effects.

20 Apr 2010

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

20 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

OECs may hold promise for pediatric cerebral palsy treatment

A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS).

19 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study

In an update of the 19,490-patient Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention, both raloxifene and tamoxifen remain effective options to prevent breast cancer at 81 months of follow-up.

19 Apr 2010

Magen Medical Solutions announces successful implantation of SpineShield anti-adhesion device

Magen Medical Solutions Ltd., a medical device company developing unique anti-adhesion devices for orthopedic applications, is pleased to announce that it has successfully implanted its first product, the SpineShield, in three patients at a clinical site in Europe.

19 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Efficacy News and Research

Updates on development of Truvada and TMC278

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Liquidia Technologies adds PPD to Series C financing

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Endosense releases TactiCath force-sensing ablation catheter

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

AngioDynamics commences treatment in NanoKnife IRE System pilot study for HCC

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

NanoBio to develop intranasal vaccine for HBV

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Homeopathy – Is it a safer and effective alternative?

OECs may hold promise for pediatric cerebral palsy treatment

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study

Magen Medical Solutions announces successful implantation of SpineShield anti-adhesion device

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News